119 related articles for article (PubMed ID: 29494842)
21. Computational Drug Repositioning for Chagas Disease Using Protein-Ligand Interaction Profiling.
Juárez-Saldivar A; Schroeder M; Salentin S; Haupt VJ; Saavedra E; Vázquez C; Reyes-Espinosa F; Herrera-Mayorga V; Villalobos-Rocha JC; García-Pérez CA; Campillo NE; Rivera G
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560043
[TBL] [Abstract][Full Text] [Related]
22. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
de Oliveira Filho GB; Cardoso MVO; Espíndola JWP; Oliveira E Silva DA; Ferreira RS; Coelho PL; Anjos PSD; Santos ES; Meira CS; Moreira DRM; Soares MBP; Leite ACL
Eur J Med Chem; 2017 Dec; 141():346-361. PubMed ID: 29031078
[TBL] [Abstract][Full Text] [Related]
23. Indazoles: a new top seed structure in the search of efficient drugs against Trypanosoma cruzi.
Aguilera-Venegas B; Olea-Azar C; Arán VJ; Speisky H
Future Med Chem; 2013 Oct; 5(15):1843-59. PubMed ID: 24144415
[TBL] [Abstract][Full Text] [Related]
24. In Silico Studies Designed to Select Sesquiterpene Lactones with Potential Antichagasic Activity from an In-House Asteraceae Database.
Acevedo CH; Scotti L; Scotti MT
ChemMedChem; 2018 Mar; 13(6):634-645. PubMed ID: 29323468
[TBL] [Abstract][Full Text] [Related]
25. Novel scaffolds for inhibition of Cruzipain identified from high-throughput screening of anti-kinetoplastid chemical boxes.
Salas-Sarduy E; Landaburu LU; Karpiak J; Madauss KP; Cazzulo JJ; Agüero F; Alvarez VE
Sci Rep; 2017 Sep; 7(1):12073. PubMed ID: 28935948
[TBL] [Abstract][Full Text] [Related]
26. High throughput screening for anti-Trypanosoma cruzi drug discovery.
Alonso-Padilla J; Rodríguez A
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3259. PubMed ID: 25474364
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, Biological Evaluation and Molecular Docking of New Benzenesulfonylhydrazone as Potential anti-Trypanosoma cruzi Agents.
Elizondo-Jimenez S; Moreno-Herrera A; Reyes-Olivares R; Dorantes-Gonzalez E; Nogueda-Torres B; Oliveira EAG; Romeiro NC; Lima LM; Palos I; Rivera G
Med Chem; 2017; 13(2):149-158. PubMed ID: 27396731
[TBL] [Abstract][Full Text] [Related]
28. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.
Duschak VG
Recent Pat Antiinfect Drug Discov; 2016; 11(2):74-173. PubMed ID: 27784230
[TBL] [Abstract][Full Text] [Related]
29. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.
Doyle PS; Zhou YM; Engel JC; McKerrow JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):3932-9. PubMed ID: 17698625
[TBL] [Abstract][Full Text] [Related]
30. Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death.
da Silva EB; Oliveira E Silva DA; Oliveira AR; da Silva Mendes CH; Dos Santos TA; da Silva AC; de Castro MC; Ferreira RS; Moreira DR; Cardoso MV; de Simone CA; Pereira VR; Leite AC
Eur J Med Chem; 2017 Apr; 130():39-50. PubMed ID: 28242550
[TBL] [Abstract][Full Text] [Related]
31. Anti-Trypanosoma cruzi activity of nicotinamide.
Soares MB; Silva CV; Bastos TM; Guimarães ET; Figueira CP; Smirlis D; Azevedo WF
Acta Trop; 2012 May; 122(2):224-9. PubMed ID: 22281243
[TBL] [Abstract][Full Text] [Related]
32. In silico, in vitro, X-ray crystallography, and integrated strategies for discovering spermidine synthase inhibitors for Chagas disease.
Yoshino R; Yasuo N; Hagiwara Y; Ishida T; Inaoka DK; Amano Y; Tateishi Y; Ohno K; Namatame I; Niimi T; Orita M; Kita K; Akiyama Y; Sekijima M
Sci Rep; 2017 Jul; 7(1):6666. PubMed ID: 28751689
[TBL] [Abstract][Full Text] [Related]
33. Polyamine metabolism in Trypanosoma cruzi: studies on the expression and regulation of heterologous genes involved in polyamine biosynthesis.
Algranati ID
Amino Acids; 2010 Feb; 38(2):645-51. PubMed ID: 19956988
[TBL] [Abstract][Full Text] [Related]
34. The Thiol-polyamine Metabolism of Trypanosoma cruzi: Molecular Targets and Drug Repurposing Strategies.
Talevi A; Carrillo C; Comini M
Curr Med Chem; 2019; 26(36):6614-6635. PubMed ID: 30259812
[TBL] [Abstract][Full Text] [Related]
35. Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
Ferreira de Almeida Fiuza L; Peres RB; Simões-Silva MR; da Silva PB; Batista DDGJ; da Silva CF; Nefertiti Silva da Gama A; Krishna Reddy TR; Soeiro MNC
Eur J Med Chem; 2018 Apr; 149():257-268. PubMed ID: 29501946
[TBL] [Abstract][Full Text] [Related]
36. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
[TBL] [Abstract][Full Text] [Related]
37. Repositioning FDA-Approved Drug Against Chagas Disease and Cutaneous Leishmaniosis by Structure-Based Virtual Screening.
Juarez-Saldivar A; Gómez-Escobedo R; Corral-Ruiz G; Chacón-Vargas KF; Horta-Montaño V; Sanchez-Torres L; Vazquez-Jimenez LK; Nogueda-Torres B; Rivera G
Arch Med Res; 2024 Feb; 55(2):102958. PubMed ID: 38290200
[TBL] [Abstract][Full Text] [Related]
38. Ligand-based virtual screening, molecular dynamics, and biological evaluation of repurposed drugs as inhibitors of
Gomes SQ; Federico LB; Silva GM; Lopes CD; de Albuquerque S; da Silva CHTP
J Biomol Struct Dyn; 2023; 41(23):13844-13856. PubMed ID: 36826433
[TBL] [Abstract][Full Text] [Related]
39. The Trypanosoma cruzi Diamine Transporter Is Essential for Robust Infection of Mammalian Cells.
Hasne MP; Soysa R; Ullman B
PLoS One; 2016; 11(4):e0152715. PubMed ID: 27050410
[TBL] [Abstract][Full Text] [Related]
40. Novel aryl β-aminocarbonyl derivatives as inhibitors of Trypanosoma cruzi trypanothione reductase: binding mode revised by docking and GRIND2-based 3D-QSAR procedures.
de Paula da Silva CH; Bernardes LS; da Silva VB; Zani CL; Carvalho I
J Biomol Struct Dyn; 2012; 29(6):702-16. PubMed ID: 22546000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
